Business Wire

GC Pharma Announces EMA Grants Orphan Drug Designation to Hunterase ICV, The World’s First Enzyme Replacement Therapy for Mucopolysaccharidosis Type II Administered by ICV ...

YONGIN, South Korea--(BUSINESS WIRE)--GC Pharma (006280.KS) today announced that the European Medicines Agency (EMA) granted orphan drug designation (ODD) to Hunterase ICV (intracerebroventricular, ...
Business Wire

Announcing Marketing Approval for Hunterase ICV Injection 15 mg, the World’s First Enzyme Replacement Therapy for Mucopolysaccharidosis Type II (Hunter Syndrome) Administered ...

YONGIN, South Korea--(BUSINESS WIRE)--GC Pharma (formerly known as Green Cross Corporation) (KRX: 006280), a South Korean biopharmaceutical company, and Clinigen K.K. (“Clinigen”), headquartered in ...
조선일보

GC Biopharma wins Peru approval for Hunterase ICV to treat Hunter syndrome

GC Biopharma said on the 6th that it received approval from the Peruvian health authority for the marketing authorization of the Hunter syndrome treatment "Hunterase ICV." Hunter syndrome is a rare ...